Current Appointments & Affiliations
Associate Professor in Medicine
·
2022 - Present
Medicine, Medical Oncology,
Medicine
Member of the Duke Cancer Institute
·
2022 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Publications
Health Insurance Payer Type and Ethnicity Are Associated with Cancer Clinical Trial Enrollment Among Adolescents and Young Adults.
Journal Article J Adolesc Young Adult Oncol · February 2022 Purpose: Adolescents and young adults (AYAs) have experienced inferior improvements in cancer survival outcomes. One potential explanation is the low rate of enrollment in cancer clinical trials. While the reasons behind this are multifactual, sociodemogra ... Full text Link to item CitePhase 1 trial of adavosertib (AZD1775) in combination with concurrent radiation and cisplatin for intermediate-risk and high-risk head and neck squamous cell carcinoma.
Journal Article Cancer · December 1, 2021 BACKGROUND: Adavosertib (AZD1775) is an inhibitor of the Wee1 kinase. The authors conducted a phase 1b trial to evaluate the safety of adavosertib in combination with definitive chemoradiotherapy for patients with newly diagnosed, intermediate-risk/high-ri ... Full text Link to item CiteThe addition of chemotherapy to adjuvant radiation is associated with inferior survival outcomes in intermediate-risk HPV-negative HNSCC.
Journal Article Cancer Med · May 2021 BACKGROUND: Only high-risk tumors with extranodal extension (ENE) and/or positive surgical margins (PSM) benefit from adjuvant therapy (AT) with concurrent chemoradiation (CRT) compared to radiation therapy (RT) in locally advanced head and neck squamous c ... Full text Link to item CiteRecent Grants
Symptom Management and Transitioning to Engagement with Post-treatment Care for Adolescent and Young Adult Cancer Survivors (AYA STEPS)
ResearchCo Investigator · Awarded by National Institutes of Health · 2024 - 2029POLARIS 2022-001: ADI-PEG 20 or Placebo Plus Gemcitabine and Docetaxel in Previously Treated Subjects with Leiomyosarcoma (ARGSARC): A Randomized, Double-Blind, Multi-Center Phase 3 Trial
Clinical TrialPrincipal Investigator · Awarded by Polaris Pharmaceuticals, Inc. · 2024 - 2029Brightline-4: A Phase III open-label, single-arm, multi-center study to assess the safety and efficacy of brigimadlin (BI 907828) treatment in patients with treatment-naive or pre-treated advanced dedifferentiated liposarcoma
Clinical TrialPrincipal Investigator · Awarded by Boehringer Ingelheim Pharmaceuticals, Inc. · 2024 - 2029View All Grants
Education, Training & Certifications
University of Wisconsin, School of Medicine and Public Health ·
2003
M.D.